Table 6.
Changes in the laboratory tests and ECG parameters between the two groups before and after treatment, medium (range)
| Variables | Wenxin Keli group | Placebo group | ||
|---|---|---|---|---|
| 0 week | 4 weeks | 0 week | 4 weeks | |
| Laboratory tests | ||||
| ALT, IU/L | 20.0 (5.6–51.0) | 23.0 (6.6–56.0) | 20.0 (6.0–45.0) | 23.2 (7.8–58.0) |
| AST, IU/L | 22.0 (7.0–48.0) | 22.0 (8.0–43.0) | 21.0 (8.0–45.0) | 22.0 (8.0–45.0) |
| Scr, mmol/L | 69.8 (40.1–136.0) | 70.0 (41.0–131.7) | 71.0 (32.0–134.2) | 68.1 (25.0–129.2) |
| BUN, mmol/L | 4.9 (2.3–19.2) | 5.0 (2.0–19.4) | 4.8 (2.2–22.3) | 4.8 (2.1–21.4) |
| ECG parameters | ||||
| Width of P wave, ms | 73.0 (30.0–130.0) | 74.0 (30.0–136.0) | 73.0 (31.0–132.0) | 74.5 (30.0–133.0) |
| PR interval, ms | 154.0 (100.0–227.0) | 158.0 (98.0–236.0) | 154.0 (102.0–246.0) | 156.0 (96.0–234.0) |
| Width of QRS wave, ms | 94.0 (52.0–151.0) | 88.0 (52.0–134.0) | 92.5 (50.0–153.0) | 87.0 (56.0–142.0) |
| QT interval, ms | 388.0 (280.0–479.0) | 382.0 (306.0–458.0) | 386.0 (284.0–464.0) | 384.0 (300.0–450.0) |
| Mean HR, bpm | 73 (60–98) | 74 (60–94) | 74 (60–98) | 74 (60–96) |
| Maximum HR, bpm | 114 (73–157) | 114 (80–151) | 115 (78–156) | 115 (75–148) |
| Minimum HR, bpm | 54 (42–74) | 55 (39–75) | 54 (42–74) | 55 (37–76) |
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Scr: Serum creatinine; BUN: Blood urea nitrogen; HR: Heart rate; ECG: Electrocardiogram.